When the USA’ Trump administration unveiled 100% tariffs on branded prescribed drugs in April 2026, India’s drugmakers breathed a sigh of reduction. The duties hit patented medicines, not the low-cost generics which can be India’s stock-in-trade, and the White Home stated the therapy of generics and biosimilars could be reassessed solely after a yr. For now, India’s strong pharma business appears tariff-proof. It isn’t, nonetheless, China-proof – and publicity is an issue not just for India, however for its Western companions.
India is, by widespread description, the pharmacy of the world. It provides shut to twenty % of the world’s generic medicines by quantity, and in 2022, Indian corporations accounted for round 47 % of all generic prescriptions allotted in the USA. Indian corporations provided greater than half of all American prescriptions in 5 of the ten largest remedy areas, together with hypertension, psychological well being and lipid regulators.
But this formidable export machine runs on borrowed chemistry. India sources round 70 % of its bulk-drug imports from China, and the reliance has, if something, deepened lately. Chinese language suppliers accounted for about 73 % of India’s energetic pharmaceutical ingredient (API) imports within the first half of fiscal yr (FY) 2026, up from 68 % in FY2019. For on a regular basis staples akin to paracetamol, penicillin and ibuprofen, China’s share of India’s imports exceeds 90 %. This dependence is not at all distinctive to India; China accounts for roughly 40 % of world API output. The explanations for its success are apparent: China gives larger economies of scale, cheaper energy and effluent therapy, and sustained state help.
India’s dependence on China has geoeconomic implications – and never just for India. Most provide chain danger is mapped bilaterally, as one nation’s publicity to a different. The pharmaceutical chain calls for a distinct geometry, as a result of dependence right here is transitive. Sufferers in the USA, the UK, and throughout the International South depend on Indian formulations, which in flip depend on key beginning supplies from China. Every hyperlink on this chain inherits the vulnerabilities of the one earlier than it.
This implies the USA is uncovered to China not solely instantly, however by means of India. Had been Beijing to limit API or intermediate exports – because it has already proven itself keen to do with uncommon earths, deploying export controls as devices of statecraft – the disruption wouldn’t be contained inside Indian factories. It might cascade into the American generic system and into the U.Ok. Nationwide Well being Service, which is determined by India for roughly a 3rd of its generic medicines. Beijing’s leverage at a single upstream node is, in impact, amplified all through the downstream accomplice ecosystem in India.
In April 2026, Indian exporters warned of falling inventories of solvents and key beginning supplies because the West Asia disaster disrupted commerce routes and lifted petrochemical costs – with some uncooked materials prices rising 20 to 30 % earlier than provides stabilized. India’s pharma business, and the healthcare of sufferers around the globe, are susceptible to any shock that begins upstream, whether or not that stems from a disturbance in freight and vitality markets (as we noticed this yr) or future Chinese language coverage.
Domestically, New Delhi has begun to behave. The Manufacturing-Linked Incentive scheme for bulk medication has helped restart home manufacturing of penicillin G and associated molecules after a niche of greater than twenty years, commissioning capability for 28 of 41 recognized essential merchandise. The progress is actual however partial. A base hollowed out over 20 years won’t be rebuilt by sales-linked incentives alone, and expanded Indian API output has tended to circulate into exports relatively than weaning the home business off Chinese language inputs.
However India’s API downside will not be merely a slim concern for home business, and thus rising Indian self-reliance ought to be a part of its exterior financial diplomacy. Financing India’s API and key beginning materials base is how the West can safe its personal pharmaceutical resilience. That is mutual leverage relatively than one-way help. The identical logic ought to govern essential minerals, photo voltaic modules, and batteries, the place India is once more a midstream node whose Chinese language dependencies, if left uncured, turn out to be everybody’s dependencies. Co-investment in bulk drug parks, joint qualification of non-Chinese language sources, and shared stockpiling of important intermediates would convert a personal price for Indian corporations right into a public good for the partnership.
The timing favors precisely this type of cut price. India has simply concluded a landmark free commerce settlement with the European Union, is deep in a extra transactional commerce monitor with the USA, and is constructing out a Nationwide Essential Minerals Mission explicitly geared toward slicing import dependence. Every of those channels is a pure automobile for embedding provide chain safety by means of trusted provider preparations, conformity requirements, and co-financing, relatively than leaving it to industrial coverage alone.
The strategic dialog ought to due to this fact transfer on from “India as an alternative choice to China” towards “India because the load-bearing node whose vulnerabilities are shared.” For New Delhi, that may be a extra flattering and extra sturdy proposition: its pursuit of self-reliance in strategic inputs will not be parochial industrial coverage however a contribution to allied provide chain safety.
For India’s companions, the uncomfortable reality is that they can’t insulate themselves from China by routing by means of India so long as India stays tethered to China. A tariff wall can preserve out a completed tablet, however can not preserve out the chemistry inside it.
